Beksac Alp Tuna, Carbonara Umberto, Abou Zeinab Mahmoud, Meagher Margaret, Hemal Sij, Tafuri Alessandro, Tuderti Gabriele, Antonelli Alessandro, Autorino Riccardo, Simone Giuseppe, Derweesh Ithaar H, Kaouk Jihad
Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.
Department of Urology, Virginia Commonwealth University, Richmond, Virginia, USA.
J Endourol. 2022 Oct;36(10):1296-1301. doi: 10.1089/end.2021.0954.
As the experience with robot-assisted partial nephrectomy (RAPN) grows, the indications have expanded to incorporate previously operated ipsilateral kidneys with recurrent renal masses. We sought to analyze the outcomes of redo RAPN in patients with a recurrent renal mass. Using a multi-institutional series, the data of 72 patients who underwent RAPN for a recurrent renal mass between 2010 and 2020 were retrospectively analyzed. Patients with familial renal cell carcinoma and multiple renal tumors were excluded. Major complication was defined by Clavien grade ≥3. The median follow-up was 28.5 months. Baseline demographics, clinical and tumor characteristics, and perioperative and postoperative outcomes are reported. Our cohort consisted of a combination of previous thermal ablation (19.6%), laparoscopic (19.6%), open (26.1%), and robotic (34.8%) partial nephrectomy. The median R.E.N.A.L. score was 8. Twenty percent had hilar tumors and 9.7% had a solitary kidney. RAPN was completed in all cases. Two cases (2.8%) were converted to open surgery. None of the cases were converted to radical nephrectomy intraoperatively. One patient underwent radical nephrectomy postoperatively because of bleeding. Transfusion rate was 5.9% and major complication rate was 8.3%. Median length of stay was 3 days. Estimated glomerular filtration rate preservation was 78.7% at discharge and 90.8% at 1-year follow-up. Positive surgical margin rate was 8.3%. Overall, distant recurrence was seen in 11 patients (15.3%), however, only 1 patient had local progression (1.4%). In experienced hands, RAPN is an effective approach to treat select cases of locally recurrent renal masses with promising perioperative and functional outcomes. Patients should be carefully monitored for distant recurrence.
随着机器人辅助部分肾切除术(RAPN)经验的积累,其适应证已扩大到包括既往接受过手术的同侧肾脏复发性肾肿块。我们试图分析复发性肾肿块患者再次行RAPN的结果。利用一个多机构系列研究,对2010年至2020年间72例行RAPN治疗复发性肾肿块的患者数据进行回顾性分析。排除患有家族性肾细胞癌和多发肾肿瘤的患者。主要并发症定义为Clavien分级≥3级。中位随访时间为28.5个月。报告了基线人口统计学、临床和肿瘤特征以及围手术期和术后结果。我们的队列包括既往接受过热消融(19.6%)、腹腔镜(19.6%)、开放(26.1%)和机器人(34.8%)部分肾切除术的患者。中位RENAL评分是8分。20%的患者有肾门肿瘤,9.7%的患者为孤立肾。所有病例均完成了RAPN。2例(2.8%)转为开放手术。术中无一例转为根治性肾切除术。1例患者术后因出血接受了根治性肾切除术。输血率为5.9%,主要并发症发生率为8.3%。中位住院时间为3天。出院时估计肾小球滤过率保留率为78.7%,1年随访时为90.8%。手术切缘阳性率为8.3%。总体而言,11例患者(15.3%)出现远处复发,然而,只有1例患者出现局部进展(1.4%)。在经验丰富的医生手中,RAPN是治疗局部复发性肾肿块特定病例的有效方法,围手术期和功能预后良好。应密切监测患者是否发生远处复发。